Literature DB >> 15378442

Tolerance to vancomycin in pneumococci: detection with a molecular marker and assessment of clinical impact.

Carina A Rodriguez1, Robyn Atkinson, Wally Bitar, Cynthia G Whitney, Kathryn M Edwards, Lauren Mitchell, Juan Li, Jack Sublett, Chin-Shang Li, Tiebin Liu, P Joan Chesney, Elaine I Tuomanen.   

Abstract

BACKGROUND: Vancomycin is often added to therapy for meningitis caused by Streptococcus pneumoniae. Tolerant bacteria without classic resistance that escape killing by multiple antibiotics have been reported sporadically. We determined the prevalence of tolerance to vancomycin in pneumococci and its effect on the outcome of meningitis.
METHODS: Archival samples of 215 nasopharyngeal (NP) and 113 meningitis isolates were tested for the killing efficacy of vancomycin. Specific DNA sequence changes in a transporter locus were identified for tolerant isolates. Similar tests were conducted prospectively on 517 NP isolates from healthy children.
RESULTS: In archival isolates, tolerance to vancomycin was detected in 3.7% of NP and 10.6% of invasive isolates. Patients with meningitis caused by tolerant isolates had a worse estimated 30-day survival than did patients with meningitis caused by nontolerant isolates (49% vs. 86%; P = .048); 62.5% of tolerant archival NP isolates harbored a specific sequence change for pep27 and vex2 (P = .021). Prospective analysis of 517 carriage isolates indicated that 8.1% were tolerant to vancomycin and that 82.1% of tolerant isolates harbored the specified marker gene sequences (P = .001).
CONCLUSIONS: Tolerance to vancomycin exists in the population of pneumococci. Tolerant isolates are associated with meningitis of increased mortality, and these isolates can be tracked by specific marker sequences in 2 genes. Copyright 2004 Infectious Diseases Society of America

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15378442     DOI: 10.1086/424467

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

1.  Inhibitory and bactericidal activities of daptomycin, vancomycin, and teicoplanin against methicillin-resistant Staphylococcus aureus isolates collected from 1985 to 2007.

Authors:  Maria M Traczewski; Bradley D Katz; Judith N Steenbergen; Steven D Brown
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

2.  Quinupristin-dalfopristin nonsusceptibility in pneumococci from sickle cell disease patients.

Authors:  Caroline A Obert; Martha L Miller; Jeremy Montgomery; Thomas Adamkiewicz; Elaine I Tuomanen
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

3.  Vancomycin-tolerant Streptococcus pneumoniae in Korea.

Authors:  Heungsup Sung; Hee Bong Shin; Mi-Na Kim; Kyungwon Lee; Eui-Chong Kim; Wonkeun Song; Seok Hoon Jeong; Wee-Gyo Lee; Yeon-Joon Park; George M Eliopoulos
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

4.  Treatment of Drug-resistant Pneumococcal Meningitis.

Authors:  Nida Hameed; Allan R Tunkel
Journal:  Curr Infect Dis Rep       Date:  2010-07       Impact factor: 3.725

5.  Revising the role of the pneumococcal vex-vncRS locus in vancomycin tolerance.

Authors:  Wolfgang Haas; Jack Sublett; Deepak Kaushal; Elaine I Tuomanen
Journal:  J Bacteriol       Date:  2004-12       Impact factor: 3.490

Review 6.  Pneumonia and Invasive Pneumococcal Diseases: The Role of Pneumococcal Conjugate Vaccine in the Era of Multi-Drug Resistance.

Authors:  Chiara Scelfo; Francesco Menzella; Matteo Fontana; Giulia Ghidoni; Carla Galeone; Nicola Cosimo Facciolongo
Journal:  Vaccines (Basel)       Date:  2021-04-22

7.  TDtest: easy detection of bacterial tolerance and persistence in clinical isolates by a modified disk-diffusion assay.

Authors:  Orit Gefen; Betty Chekol; Jacob Strahilevitz; Nathalie Q Balaban
Journal:  Sci Rep       Date:  2017-02-01       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.